Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy | Zendy

Jintanat Ananworanich | Zendy; Reto Nüesch | Zendy; Hélène C. F. Côté | Zendy; Stephen J. Kerr | Zendy; Andrew Hill | Zendy; Thidarat Jupimai | Zendy; Naphassanant Laopraynak | Zendy; S. Saenawat | Zendy; Kiat Ruxrungtham | Zendy; Bernard Hirschel | Zendy

Open Access

Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy

Author(s) -

Jintanat Ananworanich,

Reto Nüesch,

Hélène C. F. Côté,

Stephen J. Kerr,

Andrew Hill,

Thidarat Jupimai,

Naphassanant Laopraynak,

S. Saenawat,

Kiat Ruxrungtham,

Bernard Hirschel

Publication year - 2008

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn097

Subject(s) - stavudine , didanosine , lamivudine , mitochondrial toxicity , lipoatrophy , toxicity , pharmacology , zidovudine , reverse transcriptase inhibitor , biology , medicine , viral load , virology , viral disease , human immunodeficiency virus (hiv) , hepatitis b virus , virus , antiretroviral therapy

Stavudine is widely used in Thailand and is associated with mitochondrial toxicity. Here, we evaluated the effect of switching from stavudine/didanosine to tenofovir/lamivudine on measures of metabolic and mitochondrial toxicity in Thai patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research